Form 4: PTC Therapeutics CEO Matthew Klein Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO Matthew B. Klein of PTC Therapeutics sold shares of common stock on January 7th and 8th, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
Summary
- Matthew B. Klein, CEO of PTC Therapeutics, sold shares of the company's common stock on January 7, 2025, and January 8, 2025.
- These sales were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
- On January 7, 2025, 2,142 shares were sold at a price of $45.34 per share.
- On January 8, 2025, 2,402 shares were sold at a price of $44.50 per share.
- Following these transactions, Klein directly owns 283,830 shares of PTC Therapeutics common stock.
Sentiment
Score: 6
Explanation: The document reflects routine transactions related to executive compensation. It's neutral as it doesn't indicate any fundamental changes in the company's prospects.
Industry Context
Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/05/2023 | Grant of 26,000 RSUs |
| 01/06/2021 | Grant of 9,000 RSUs |
| 01/07/2022 | Grants totaling 41,000 RSUs |
| 01/07/2025 | Sale of 2,142 shares at $45.34 |
| 01/08/2025 | Sale of 2,402 shares at $44.50 |
| 01/10/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.